Of These Three, Which Is The Right Choice? Entegris Inc (ENTG), Angie’s List Inc (ANGI) and Pacific Biosciences of California (PACB)

Posted by admin May 4, 2015 0 Comment 450 views

New York, NY – GDP INSIDER  –  05/04/2014.

This article discusses three companies: Entegris Inc (NASDAQ:ENTG), Angie’s List Inc (NASDAQ:ANGI) and Pacific Biosciences of California (NASDAQ:PACB)

Entegris Inc (NASDAQ:ENTG) resumed its steady climb on Friday with the stock gaining 0.75% or $0.10 to close at $13.41. The manufacturer and supplier of microelectronics and other high tech products has gained a total of 20.16% over the last one year and has been closely tracking and mostly outperforming the S&P 500. The S&P 500 has only gained 11.87% over the same period. With strong quarterly revenue growth of 58.90% year on year, one year target estimate for the stock is is quite achievable, making it a potential medium term buy at this time.

Is Entegris Inc Moving In A Right Direction? Click Here For Free ENTG Analysis.

Angie’s List Inc (NASDAQ:ANGI) declined slightly during Friday’s trading session with the stock closing down 0.34% or $0.02 to finish the day at $5.85, on light trading of 1.418 million shares, compared to its three month average trading volume of 1.97 million. The self managed real estate investment fund has been trading within a range of $5.64 and $5.98 over the last 12 months recently and has been underperforming the S&P 500 for most of this year. However, the Angie’s List Inc is now down only 6.10% YTD compared to the S&P 500 which has gained only 2.4% over the same period, making it a hold at this time.

Do Angie’s List Inc’s Fundamentals Show More Gains? Get The Complete Picture With Free ANGI Analysis.

Pacific Biosciences of California (NASDAQ:PACB) jumped on Friday with the stock climbing 9.88% or $0.51 to close at $5.67 on very active trading of 1.032 million shares, compared to its three month average trading volume of 0.751 million. The developer and distributor of tools for biological research has been declining for most of this year so far, with the stock down 27.86% YTD. However, Pacific Biosciences of California Inc has been enjoying quarterly revenue growth of 85.70% year on year and has diluted EPS of -$0.94, indicating that the stock could turn around. At this price it may be worth investing in for the medium term.

Do Pacific Biosciences of California’s Fundamentals Support Further Growth? Click Here For Free PACB Analysis.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.

Write Your Comment